Long-term alendronate therapy and subtrochanteric femoral fractures

Ochsner Journal

Volumn 10, Issue 1, 2010, Pages 22-

  Pasala, Satish ^a   Burshell, Alan ^a   Ogden, Field ^b,c,d  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Southern Orthopaedic Specialists   (United States)

^c Ochsner Baptist Medical Center   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alendronate; Subtrochanteric femoral fracture; Suppressed bone turnover

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BONE DENSITY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FALLING; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; STRESS FRACTURE; VITAMIN BLOOD LEVEL;

EID: 77954532413     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Odvina CV, Zerwekh ZE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-1301.
2. Frost HM. Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull. 1960;8:27-35
3. Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009;64(1):18-23.